<SEC-DOCUMENT>0001193125-13-362123.txt : 20130910
<SEC-HEADER>0001193125-13-362123.hdr.sgml : 20130910
<ACCEPTANCE-DATETIME>20130910074536
ACCESSION NUMBER:		0001193125-13-362123
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20130910
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130910
DATE AS OF CHANGE:		20130910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		131086859

	BUSINESS ADDRESS:	
		STREET 1:		11494 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1318
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		11494 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d595668d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of
earliest event reported) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;10, 2013 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1787 Sentry Parkway West</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Building 18, Suite 400</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Blue Bell,&nbsp;Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19422</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: <U>(267)&nbsp;440-4200</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;7.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Regulation FD Disclosure</U>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;10, 2013, we issued a press release to
announce that we have entered into a Collaboration, Option and License Agreement dated as of September&nbsp;9, 2013 (the &#147;Agreement&#148;) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#147;Roche&#148;). A copy of the
press release is attached as Exhibit 99.1 to this Form 8-K current report and is incorporated by reference into this Item&nbsp;7.01. We will file a separate Form 8-K with respect to the Agreement to report the entry into a material definitive
agreement under Item&nbsp;1.01 of Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;10, 2013, we are holding a conference call at 8 a.m. eastern time to
discuss the Agreement and our strategic partnership with Roche. The script for this conference call is attached as Exhibit 99.2 to this Form 8-K current report and is incorporated by reference into this Item&nbsp;7.01. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;9.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated September 10, 2013.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Script for Conference Call of September 10, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September&nbsp;10, 2013 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d595668dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><I>Media Release</I></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g595668ex99_1pg01.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basel, Switzerland and Blue Bell, PA, USA &#150; 10&nbsp;September 2013 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roche and Inovio Pharmaceuticals partner on Inovio&#146;s prostate cancer and hepatitis B immunotherapy products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche (SIX: RO, ROG; OTCQX: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that they have entered into an exclusive worldwide license
agreement to research, develop and commercialize Inovio&#146;s highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust
T-cell responses in animal models. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche acquired an exclusive license for Inovio&#146;s DNA-based vaccines INO-5150 (targeting prostate cancer) and
INO-1800 (targeting hepatitis B) as well as the use of Inovio&#146;s CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> electroporation technology for delivery of the vaccines. Roche also obtained an option to license additional
vaccine opportunities in connection with a collaborative research program in oncology. Roche and Inovio will collaborate to further develop INO-5150 and INO-1800. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&amp;D support and
payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche
pursues other indications with INO-5150 or INO-1800. In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenting on the deal, Hy Levitsky, Head of Cancer Immunology Experimental Medicine at Roche, said: &#147;At Roche we are always interested in finding
first-in-class and best-in-class therapies that may become the next generation treatments for patients with different types of cancer. INO-5150 will allow promising combination opportunities with the Roche portfolio, particularly with our emerging
cancer immunotherapy molecules.&#148; Janet Hammond, Head of Infectious Diseases Discovery&nbsp;&amp; Translational Area at Roche, added: &#147;We are very excited to have this potentially very important and novel mechanism of action as part of our
portfolio as we seek to address the significant unmet medical need in chronic hepatitis B infection.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1/5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This partnership represents an important milestone in Inovio&#146;s growth and maturing product portfolio.
Roche brings to our immunotherapy candidates its leadership position and track record for developing and marketing innovative first-in-class therapies,&#148; said Dr.&nbsp;J. Joseph Kim, Inovio&#146;s President and CEO. &#147;Collaborating with the
world&#146;s preeminent oncology development partner allows us to rapidly advance two of our promising near-clinical stage immunotherapy products from our product pipeline as we continue development of our phase II lead product, VGX-3100, for
treatment of HPV-related cancers and dysplasia.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- ### - </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INO-5150 for Prostate Cancer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio&#146;s
dual-antigen synthetic DNA vaccine (INO-5150) targets prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA). A study in monkeys showed that vaccination with INO-5150 generated strong and robust T-cell immune responses that
were the highest generated by a PSA-based immunotherapy in animal studies and were similar to the immune responses generated by VGX-3100, Inovio&#146;s phase II-stage therapeutic HPV vaccine that generated best-in-class T-cell responses in a phase I
study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio&#146;s SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> DNA vaccine for prostate cancer was designed with PSA and PSMA
synthetic consensus immunogens based on human and macaque sequences, resulting in amino acid sequences that differ slightly from the native human protein. In humans, this novel approach is utilized to help the body&#146;s immune system recognize
cancerous cells created in the body as &#145;foreign&#146;, overcoming the body&#146;s self-tolerance of these cells and mounting an immune response to clear them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INO-1800 for Hepatitis B </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio has reported
preclinical data showing its hepatitis B vaccine (INO-1800) generated strong T-cell and antibody responses that led to the elimination of targeted liver cells in mice. These results indicate this DNA vaccine&#146;s potential to treat hepatitis B
infection and prevent further development of the infection into liver cancer in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a preclinical study, researchers found the vaccine-specific
T-cells exhibited a killing function, and could migrate to and stay in the liver and cause clearance of target cells without evidence of liver injury. This was the first study to provide evidence that intramuscular immunization can induce killer
T-cells that can migrate to the liver and eliminate target cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2/5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To provide worldwide rights to Roche, Inovio has re-acquired its hepatitis B, Asian-country rights from
Inovio&#146;s international affiliate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disease Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prostate Cancer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prostate cancer is the second most
frequently diagnosed cancer of men. Nearly three-quarters of the registered cases occur in developed countries. Accounting for nearly 300,000 deaths each year, prostate cancer is the sixth leading cause of death from cancer in men. The development
of a new treatment for prostate cancer would be a significant medical advancement given that present treatment options (surgery, radiation and hormone deprivation), while somewhat effective, all carry deleterious side effects and are often not a
long-term cure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hepatitis B and Liver Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hepatitis B is a disease characterized by inflammation of the liver. The virus is extremely infectious &#150; 100 times more so than HIV &#150; and
400&nbsp;million people are chronically infected worldwide. Hepatitis B contributes to an estimated 1&nbsp;million deaths worldwide each year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liver
cancer is the third most common cancer and the most deadly, killing most patients within five years of diagnosis. About 600,000 new cases arise each year. One of the major causes and risk factors for liver cancer is infection by hepatitis B. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is
revolutionizing vaccines to prevent and treat today&#146;s cancers and challenging infectious diseases. Its SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> vaccines, in combination with its proprietary electroporation delivery, are
generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio&#146;s lead vaccine, a
therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the
University of Pennsylvania, Merck, NIH, HIV Vaccines </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3/5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative.
More information is available at <U>www.inovio.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Roche </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the
world&#146;s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a
frontrunner in diabetes management. Roche&#146;s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over
82,000 employees worldwide and invested over 8 billion Swiss francs in R&amp;D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in
Chugai Pharmaceutical, Japan. For more information, please visit <U>www.roche.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain forward-looking statements
relating to Inovio&#146;s partnership with Roche related to Inovio&#146;s Hepatitis B and prostate cancer immunotherapeutic products, in addition to Inovio&#146;s business, including our plans to develop other electroporation-based drug and gene
delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein, including realization of any and all projected development or sales milestone payments, as a result of a
number of factors, including Roche&#146;s change in business resulting in the amendment or termination of the Agreement, uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to,
the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that
pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an
animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or
develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be
more efficacious or cost-effective than any therapy or treatment that the company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4/5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the
company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the
company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s technology by potential corporate or other partners or
collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2012, our Form 10-Q for the quarter ended June&nbsp;30, 2013,
and other regulatory filings from time to time. There can be no assurance that any product in Inovio&#146;s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Roche Partnering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emilie Vincent, Head of Roche
Partnering Communications, <U>emilie.vincent@roche.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inovio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Bernie Hertel, Inovio Pharmaceuticals, +1858-410-3101, <U>bhertel@inovio.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: Jeff Richardson, Inovio Pharmaceuticals, +1 267-440-4211, <U>jrichardson@inovio.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5/5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d595668dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="3" VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Inovio</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Pharmaceuticals</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Investor Conference Call Script</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Dr.&nbsp;J. Joseph Kim</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President and CEO</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Inovio Pharmaceuticals, Inc.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">September&nbsp;10, 2013</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bernie Hertel: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Good morning. And, thank you for joining us today. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
conference call may contain certain forward-looking statements relating to Inovio&#146;s partnership with Roche related to Inovio&#146;s Hepatitis B and prostate cancer immunotherapeutic products, in addition to Inovio&#146;s business, including our
plans to develop other electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations discussed, including realization of any and all projected
development or sales milestone payments, as a result of a number of factors, including Roche&#146;s change in business resulting in the amendment or termination of the Agreement, uncertainties inherent in pre-clinical studies, clinical trials and
product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this conference may not be indicative of results achievable in other trials or for other indications, that the studies or
trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by
the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving
product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or
infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate
expenditures, assessments of the company&#146;s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form
10-K for the year ended December&nbsp;31, 2012, our Form 10-Q for the quarter ended June&nbsp;30, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio&#146;s pipeline will be successfully
developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information discussed will be proven accurate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, Dr.&nbsp;J. Joseph Kim, President &amp; CEO of Inovio Pharmaceuticals: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you, Bernie. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Earlier this morning Roche, the
world&#146;s preeminent oncology company, and Inovio Pharmaceuticals, the world&#146;s leading DNA based vaccine and immunotherapy company, announced a major strategic partnership. In this call I will discuss what this partnership means for Inovio,
for our shareholders and for patients. I will also offer a brief overview of Inovio&#146;s broad pipeline of DNA therapies and then take questions from the analysts on the call today. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First, what a fantastic opportunity for Inovio and its shareholders to partner with Roche. This transaction rewards the confidence we have always held in our
synthetic DNA vaccine and electroporation delivery platform. That&#146;s because most partnerships usually occur at later stages of clinical development after efficacy trials are completed. Our partnership with Roche is for preclinical products and
demonstrates how others value our technology and potential. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Today&#146;s agreement offers Inovio and its shareholders immediate, near-term and long-term benefits. It
provides validation of our novel technology for treating and preventing diseases, provides non-dilutive funding, and allows us to accelerate our product development pipeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche and Inovio have entered into an exclusive worldwide licensing and collaboration agreement to develop and commercialize Inovio&#146;s DNA immunotherapies
targeting prostate cancer and Hepatitis B. Roche has licensed these DNA-based products and the use of Inovio&#146;s CELLECTRA electroporation technology for the delivery of these products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All products in this agreement are at a near-clinical stage. Our prostate and Hepatitis B DNA immunotherapies have each generated robust T-Cell responses in
small and large animals, signaling their potential to treat disease in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apart from the license for INO-5150, Inovio&#146;s immunotherapy for
prostate cancer, and INO-1800, our Hepatitis B therapy, Roche has also secured an exclusive license to any further immunotherapy candidates resulting from the collaboration in these two disease areas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Roche will make an upfront payment of $10 million to Inovio. Roche will also provide preclinical R&amp;D support and
payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues
other indications with INO-5150 or INO-1800. In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, let me give you some background on the
products we&#146;ve licensed today. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INO-5150 is a prostate cancer immunotherapy that is different from other candidates in two ways: First, it targets
both the prostate-specific membrane antigen and the prostate-specific antigen, unlike other single-antigen treatments. Second, using our novel synthetic consensus methodology we have incorporated a unique design feature that may help break the
body&#146;s tolerance of cancerous prostate cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I would like to emphasize what a novel prostate cancer treatment would mean &#150; prostate cancer
kills 300,000 men each year and is the second most frequently diagnosed cancer in men. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current treatments, while somewhat effective, leave many men with
harsh side-effects and often with recurring cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our prostate cancer product is close to phase I IND filing and we are finalizing the specific study
protocol and other clinical details with our colleagues at Roche. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second product, INO-1800, is an immunotherapy for Hepatitis B &#150; which is 100
times more infectious than the HIV virus. Hepatitis B is one of the major causes of liver cancer, with 600,000 new cases each year. This cancer kills most patients within 5 years of diagnosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio previously reported preclinical data in mice showing that INO-1800 generated best-in-class T-Cell and antibody responses, as published in a
peer-reviewed publication. This was the first study ever to show that an immunotherapy targeting Hepatitis B could induce killer T Cells that migrate to the liver and achieve a killing effect against targeted liver cells. These results indicate
INO-1800&#146;s potential to treat human Hepatitis B infection and prevent progression of the infection into liver cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To give you a sense of
INO-1800&#146;s development timeline, we are ready to manufacture clinical product and completing other tasks to support our IND filing. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the effort to conclude this transaction, Inovio re-acquired the Hepatitis B rights for Asian countries
from its affiliate, VGX International, in exchange for 10% of development milestone payments and royalties, but excluding any R&amp;D support payments. I should add Inovio holds an equity interest in VGX International. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Inovio, this partnership is a watershed event. So, I&#146;d like to make clear to our long-term and new shareholders Inovio&#146;s accomplishments that
led up to this announcement today and give you a look at where our efforts will be placed going forward. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio&#146;s mission is to revolutionize
vaccines. We are re-defining vaccines with a 21<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> century technology, called DNA vaccines, to prevent and treat today&#146;s cancers and challenging infectious diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First, some history. In 2009 a merger brought together two powerful technologies&#133;.and the emergence of the new Inovio Pharmaceuticals provided the
foundation for the leaders of DNA vaccines and electroporation delivery to forge a new path of highly-optimized design and synergistic development of this now-integrated platform &#150; which is protected by a dominant global patent portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scientists have long perceived the important role T Cells could play in conquering cancer and challenging infectious diseases &#150; only to find the door to
new therapies locked. Inovio&#146;s eminent scientists and world-renowned advisors have unlocked those doors and created multiple immunotherapy products targeting multiple diseases &#150; all with the goal of inducing strong T-Cell responses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Already, in multiple disease areas, we have demonstrated in animal and human studies that our technology is generating best-in-class T-Cell immune responses.
These diseases include pre-cancerous cervical dysplasias caused by the HPV virus, as well as HIV. We also showed robust vaccine-induced T Cells against cancers that express the HTERT antigen &#150; which is found in 85% of all cancers. Other disease
targets showing our T-Cell prowess include prostate cancer, malaria, and Hepatitis C and B. Overall, our immunotherapy products, delivered using our proprietary electroporation technology, are generating T-Cell responses that exceed all other
approaches as measured by magnitude, breadth and response rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, theses antigen-specific T Cells are displaying a killing effect against the
cells they are designed to target. These compelling immune responses are what attracted a company like Roche to engage Inovio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While this deal provides
the resources to allow Inovio to co-develop products targeting two important medical markets, I want to emphasize that this partnership enhances our ability to advance other products in our pipeline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio&#146;s novel synthetic consensus vaccine design has not only been employed in the two immunotherapies we out-licensed today, it is fundamental to the
design of all of our vaccines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Let me provide a quick review of those products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First, Inovio&#146;s lead cancer product &#150; VGX-3100. It is a DNA vaccine designed to treat HPV-caused pre-cancers and cancers. In a human study, which
was published in an article in the prestigious <U>Science Translational Medicine</U> journal, this immunotherapy demonstrated a powerful killing affect against cells that showed markers of HPV infection. This desirable effect may ultimately
contribute to the regression or elimination of these cells. We expect results from our ongoing phase II efficacy study in women with late-stage cervical pre-cancer in mid-year 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also expect to begin efficacy trials with VGX-3100 in HPV-caused cancers including head&nbsp;&amp; neck, cervical and anogenital cancers during the next
year </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Staying in the cancer arena, we are planning to begin breast and lung cancer clinical studies with INO-1400, our DNA immunotherapy targeting cancers
with HTERT, in 2014. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Complementary to the Hepatitis B vaccine we licensed today, INO-8000 is Inovio&#146;s immunotherapy for hepatitis
C, which also causes liver cancer. We expect to initiate the first INO-8000 clinical trial by the end of this year with our affiliate and collaborator, VGX International. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moving to HIV vaccine development, we raised the bar with the immune responses we generated with our initial single-antigen HIV vaccine and now anticipate the
initiation of a clinical study by the end of this year of our multi-antigen HIV vaccine. This study will be funded and run by the HIV Vaccine Trial Network. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our universal flu vaccine program has shown protective immune responses against unmatched strains of multiple subtypes of this virus, including the virulent
H7N9 flu virus. Presently, we are seeking third-party funding and collaborators to continue to advance this program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also plan to advance to the
clinic our malaria DNA vaccine, which is primarily funded by PATH/MVI, established by the Gates Foundation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Turning back to today&#146;s announcement
&#150; this is an important strategic opportunity for Inovio, its shareholders, and for patients. Roche brings to our immunotherapy candidates its leadership position for developing and marketing innovative first-in-class therapies. We look forward
to our collaborative effort to develop two of Inovio&#146;s promising near-clinical stage immunotherapy products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I&#146;ll end by reminding you that no
other company can challenge Inovio&#146;s claim that we can generate the best T-Cell responses in humans. These reasons, along with the partnership we announce today, reinforce our confidence in achieving medical as well as commercial success at
Inovio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Now, I&#146;m pleased to address your questions. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g595668ex99_1pg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g595668ex99_1pg01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)P!+`P$1``(1`0,1`?_$`'(```(#`0`#````````
M``````<)``@*`P4&"P$!`````````````````````!````8"`0$$!P<%````
M`````@,$!08'`0@)`!(3%0H1%!;6%Q@9(22869D:6C%!(B,E$0$`````````
M````````````_]H`#`,!``(1`Q$`/P#?QT"9.8SE;:^.VK8Q7M/1\NZ-]=D5
MQ<&U/UX:$IC\\O<F=U06<F?RMB;U)#@3!(\O.P$.,B*&[.&`I"1!+"L4I`75
MK[Y>"X[*JQALO?7DZY&L[8V.>YSNX6JA-GE<*JF+2.4KSG841BS*.-.J?N8Z
M2H"G.-2Y3H!'A'A(04F"4'H#5^VMJ+\S+E\_&8=[B]!/VUM1?F9<OGXS#O<7
MH)^VMJ+\S+E\_&8=[B]!/VUM1?F9<OGXS#O<7H*ZUC<=]>7_`-O6C6O<"XK3
MV#XJMJI.47KSN#=LB/F=@:T72Z(T07"M[RG2H"8&(2^GHSADJ!@+3$%9+7$!
M*"!V+`&LE*J3+DR9:B4D+$:P@E4D5I3BU"94F4%A-(4ICRA#*/(/*'@0!ASD
M(@YQG&<XST'?H%W\F?(_3'&7K@ZW79?>2N<ORL,/HBD&)3@4^O*TW+)2=CAD
M3;""5C@-*6H4EG.:X"<X"!)]O9,/,3ISP7IQ&<:MOH[&DG*QR7"(G/(WL.V!
M51^-N!!G@.H-0NR(/@%/0AC4=I-'Y2B9E.4SF87@1R(L9B,)HSC7%0L!&<FY
MS>:2&5[N_O`S/NHD\U1T@WO=M7IG3,IKQ[CECR2-*Y\7'8^N99(P*"B<Y)3O
M#<C-4Y5Y5%'&C4B2GE%"`,-=EB\G.C]"QVDE^SNRE,ZZRF]*]BMAQ2#638#.
MUOF&B3MS>JPI-+-R2:4S(UJ[*7Q)04F1F&DF>@>.[,P`"GL!O#I_JM`H=:&Q
M&R-/U)7]BC2@KZ52Z;,R1KG85K<4[IU$-&0H4&RA$-I4%*LJ$(#R`)S2S!#P
M`8,Y!%W-5R]S+6B)<7EV:8;*58'7O9O:!)%[;M-L1U[8\&D-,(542,DQY,F>
M&]]2QTAF;E;AE8H1C3K$HBQA&(`RNS@'AT]OII=?]33R]J;V@I.P*>JW+A\3
M+%8Y\PYB]>@:T(G1:=-G!6K2@BZ8MM#E0$U;@@LTC&3`"$#[>@!PK,XUN9*@
M;IU\B]NTUMA4[XU@CEG1V"3!"YO<9,4B+5L,A(+3C+?(VZMCD26J:G0!00`6
M$8[`QY`,'0*.X[-IKHXJ]FV/AEY$YBKDM:OG;*XS=RY/DQ"QVI7Q)B!"PZZ3
M-T4%B2(9]$"U`$3=@]3G)9N`-P1"(-:,G!J8Z#')<^`4!YCB#7;RV#-D5$6!
M'0Q'BDN4W(F_6VC["PJ;AGPR;LJPU:DCUMGG*C/^XM4A`-S-3+L%@3"3#:PV
M-8SC.,9QG&<9QZ<9Q]N,XS_3.,_WQGH/DVW7J`*P-%N7[<]LLFTD[KK'R\21
M$[4I[0.#E04]BTIL9"P#>I76Y18&X4S9WJ7IQ!>#3,XRVE#1Y!_F`809O8+3
M2&PN_P#SF3#86/5K(7*)\'4#GVM<;DI#4Z06"`4ZE:_2XEXII2]DA(;#8C+W
MDD+">B-+4^A>?W?>9,-ST'I'&U'H5>6Y7EWZ\W!;(-8E.)..#8E=#(C:84+S
M6RV1MMM[6(XX0>W2DQ0QO<B3,L69`&(C<&E@R@2!P2'!90<!X/=ZNN,!OJKC
M@J[C@L6>WKK2LYF5+/:C';":2.$48Y_(FVF6Z802&H9=`X.C50-UBP4@CBDA
M*U&?@WM"/%D>?2`MY`X6PTNS^:'K*EX^FK6M&?9GC@2%P2`I11^&-3'()[/W
MUV1%1YIP0SMC*JDHR#,%`*+3E&9+*+P$&0EY!L'#CK_8--\W$+<I-8/';!94
M]<<S.1(]<=&6V\4C"\4T>SPE77=H.;D]0PRMWF<NKBD9SW50?(SEBPD>%0"#
M!&X/$#;_`#,DLU&%H4"G+RB#W9FREPS!L9=#J]K,?<WF?L<0O;4K!+J]<$[>
MYKF5EC1CJ3A]-[KNEJ)2%`'[VK2Y"%6?EX\QW[">I?'U@^(/T5OAQXSXDG\$
M^=_YC_'_`%3U+VE[7S)_+%_P?B!V/`_:#[UW/H_V=!H=WFTFHOD'UKL#6#8.
M/`>83-T/>-SNE*2^TD$EJ(!HH[/(:O4DGX:Y-'51N1E&8QV3B1FIS<#(.-+$
M"7^+W=&[]-+_`$_"SR928:RY(HV8SH?M$\X5D1_<.C6X:M)'V!6[KE*TLNVH
MHVH,)\)SE)BE6`D:0T0UJ8LYQ!F:7B/T+147M#K>13)H:@W(LPVW]A(P*:S0
M8IM/SI(RRT3T4ZB?<NC"$+]'DAX2$!R<@/==G`.SG.,@'=CN!/BVVO55&XW?
MKF.2O%*UA#Z;A[ZV6+8\3>UU;0!&C;H;&9DYQ:4-"J:D1YM1X3)SG(2A2$@8
M@9,R'`<!`D;0\,W&YN#5M(TW=.M$;4P37!DQ%Z110A[E5:N=>Q021$C4Q5G?
M8*]L3P='EP6U.8H3*3CP'*2L'B])PAC$'(7#%QO@JS6VEV_7-I9*YU-LXVYJ
M48623S%M&QV@I6MCBNFC\Z$/V':9O3@M9DHSS'8]9VPD`!Z,%@"#`$=QXN]'
M'Q]W'D$AHYJDBO?I'&4.U*5^?),Y-EE$PT"SV7'AN/>,IXRK8U"T:A,H:L(S
MR500'`'@TL`PA0H6L_$7Y<RC[JW(@E4#K98\LC?"<'GS*96/:5G.ZH_"N)TQ
M6XIU(7U62JE#TWE&#3I>Y3@+2^M*Q83(^T4`LXJ=#[PV!O1?S-\G++V]K;6:
M>[U8UU<RS%4/TLHIP("9%D#(TNF3CF^T'IE4B&J.&6G5H_7%)J@&'!:IPG#2
M1T$Z!.W,KK!H[M[1$4IC:78.H-6[J=I02YZ:WA,[)A=:V?"KR;%#>8R*:H52
M&21A]E!BQQ&D(<VAL/R:J+,*$#NE9:,\D*8Z][F>8!I2I8I4FP/#Z5M19U<I
MCH<[[$0C>&A*V:;?1,!XVUGG*N(R)JD#DA?'UM3EGK3A&DA6*!"/PE29,RF*
M`T_4<YE_X_TL_4<UH]SN@GU'.9?^/]+/U'-:/<[H)]1SF7_C_2S]1S6CW.Z"
M?4<YE_X_TL_4<UH]SN@J3!:;G&RF^D!WHYT7&CM/V2$R%+`.,SCGM/8VH)(R
J8GX2V8<AMQR<O&F=BMZUEC\J3^')$:,U6288FP,D!:1#@T-4G03H/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
